Redx Pharma plc Reversible BTK poster at ASH meeting
December 06 2016 - 2:01AM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
06 December 2016
6 December 2016
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company" or "the Group")
Pre-clinical profile of reversible BTK inhibitor RXC005
presented at ASH 2016
Redx, the drug development company, is pleased to announce that
it has presented the pre-clinical profile of its reversible
Bruton's tyrosine kinase (BTK) inhibitor RXC005 at the 58(th)
American Society of Hematology (ASH) Annual Meeting in San Diego,
California, United States, on 5 December 2016.
Redx's development candidate RXC005 is a novel, potent and
selective, reversible BTK inhibitor with efficacy and equivalent
potency against wild-type and cysteine-481 (C481) mutated BTK.
First generation BTK inhibitors, such as ibrutinib and
acalabrutinib, specifically target C481 within BTK and mutations at
this site interfere with covalent drug binding. Several mutations
have been reported and linked to cases of resistance that have
emerged in patients with chronic lymphocytic leukaemia (CLL)
progression following treatment with ibrutinib. Redx's reversible
BTK inhibitor RXC005 aims to overcome this resistance mechanism by
targeting both wild type and C481-mutated BTK.
The Company is progressing studies to prepare the RXC005 program
for first-in-human clinical trials. The aim is to commence these
trials late 2017.
Dr Neil Murray, CEO of Redx, said:
"We're delighted to have presented the compelling pre-clinical
profile of our reversible BTK inhibitor RXC005 at the ASH 2016
meeting in San Diego.
"RXC005 has the potential to become a potent therapy for chronic
lymphocytic leukaemia patients by tackling the growing resistance
to ibrutinib treatment. We aim to initiate first-in-human clinical
studies for RXC005 late 2017."
The ASH Poster for RXC005 (poster #4399) is available on the
Investor section of the Company's website:
www.redxpharma.com/investors.html
For further information, please contact:
Redx Pharma Plc
Neil Murray, Chief Executive T: +44 1625
469 900
Karl Hård, Head of Investor Relations T: +44 7491
& 651 406
Corporate Communications
Cantor Fitzgerald Europe (Nomad & Broker) T: +44 20
7894 7000
Phil Davies/ Michael Reynolds
About Redx Pharma Plc
Company website: Redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a portfolio of 14 proprietary drug programs. Seven
proof of concepts have been achieved across five programs, with
relevance for respective therapies to treat MRSA, gonorrhoea, bone
tumours, skin, brain, breast, pancreatic and blood cancers.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUVRURNSAURUA
(END) Dow Jones Newswires
December 06, 2016 02:01 ET (07:01 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024